/OBSV

OBSV Stock - ObsEva S.A.

Q: What is the analyst price target for OBSV?

Analyst price target information is not currently available for OBSV.

Q: What is OBSV's market cap?

Market capitalization information is not currently available for OBSV.

Healthcare|Biotechnology|NASDAQ

$0.10+0.00%

+$0.00 (+0.00%) • Mar 22

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+5793.9%upside

Target: $6.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for OBSV

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.67

52W High$2.14

52W Low$0.07

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$19.64M	N/A	N/A	N/A	N/A
Gross Profit	$19.64M	N/A	N/A	N/A	N/A
Gross Margin	100.0%	N/A	N/A	N/A	N/A
Operating Income	$-15,677,000	$-54,514,000	$-79,701,000	$-107,095,000	$-77,154,000
Net Income	$-29,879,000	$-58,377,000	$-82,966,000	$-108,790,000	$-76,716,000
Net Margin	-152.2%	N/A	N/A	N/A	N/A
EPS	$-0.32	$-0.78	$-1.67	$-2.49	$-1.91

Company Overview

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

50%

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

Average Target

↑ 8740.9% Upside

Now

Low

Average

$12

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 30th 2022	H.C. Wainwright	Downgrade	Neutral	-
June 3rd 2022	Cantor Fitzgerald	Initiation	Overweight	$6
April 26th 2022	Canaccord Genuity	Initiation	Buy	$12

Earnings History & Surprises

OBSV

Beat Rate

44%

Last 18 quarters

Avg Surprise

-22.9%

EPS vs Estimate

Beats / Misses

8/8

2 met exactly

Latest EPS

$-0.26

Q1 2023

EPS Surprise History

Q2 21

-3.6%

$-0.29vs$-0.28

Q3 21

0.0%

$-0.25vs$-0.25

Q4 21

+104.5%

$0.01vs$-0.22

Q1 22

-18.2%

$-0.26vs$-0.22

Q2 22

+30.0%

$-0.14vs$-0.20

Q3 22

-129.4%

$-0.39vs$-0.17

Q4 22

-57.0%

$-0.13vs$-0.08

Q1 23

-333.3%

$-0.26vs$-0.06

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 4, 2024	—	—	—	—
Q3 2023	Aug 15, 2023	—	—	—	—
Q1 2023	Mar 6, 2023	$-0.06	$-0.26	-333.3%	✗ MISS
Q4 2022	Dec 1, 2022	$-0.08	$-0.13	-57.0%	✗ MISS
Q3 2022	Aug 17, 2022	$-0.17	$-0.39	-129.4%	✗ MISS
Q2 2022	May 17, 2022	$-0.20	$-0.14	+30.0%	✓ BEAT
Q1 2022	Mar 10, 2022	$-0.22	$-0.26	-18.2%	✗ MISS
Q4 2021	Nov 4, 2021	$-0.22	$0.01	+104.5%	✓ BEAT
Q3 2021	Aug 5, 2021	$-0.25	$-0.25	0.0%	= MET
Q2 2021	May 6, 2021	$-0.28	$-0.29	-3.6%	✗ MISS
Q1 2021	Mar 5, 2021	$-0.42	$-0.32	+23.8%	✓ BEAT
Q4 2020	Nov 5, 2020	$-0.34	$-0.49	-44.1%	✗ MISS
Q3 2020	Aug 6, 2020	$-0.42	$-0.38	+9.5%	✓ BEAT
Q2 2020	May 5, 2020	$-0.48	$-0.48	0.0%	= MET
Q1 2020	Mar 5, 2020	$-0.58	$-0.48	+17.2%	✓ BEAT
Q4 2019	Nov 7, 2019	$-0.82	$-0.63	+23.2%	✓ BEAT
Q3 2019	Aug 7, 2019	$-0.60	$-0.80	-33.3%	✗ MISS
Q2 2019	May 9, 2019	$-0.51	$-0.59	-15.7%	✗ MISS
Q1 2019	Mar 5, 2019	$-0.49	$-0.46	+6.1%	✓ BEAT
Q4 2018	Nov 8, 2018	$-0.46	$-0.42	+8.7%	✓ BEAT